Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 2/20 | 0.48 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 7/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ITGA2 | P17301 | 6/20 | 0.44 |
| ▸ | PPIA | P62937 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21358708 | 1.00 | ITGA4 (0.48) | ITGA4TXNRD1ALDH1A1ITGB1MAPT | |
| SCHEMBL21358810 | 0.84 | ITGB1 (0.55) | ITGA4ALDH1A1ITGB1L3MBTL1ITGA2 | |
| SCHEMBL21358813 | 0.84 | ITGB1 (0.55) | ITGA4ALDH1A1ITGB1L3MBTL1ITGA2 | |
| SCHEMBL21376280 | 0.82 | ITGB1 (0.53) | ITGA4ITGB1ITGA2 | |
| SCHEMBL21358834 | 0.79 | ITGB2 (0.56) | ITGA4ALDH1A1ITGB1L3MBTL1ITGA2 | |
| SCHEMBL21358836 | 0.79 | ITGB2 (0.56) | ITGA4ALDH1A1ITGB1L3MBTL1ITGA2 | |
| SCHEMBL21358862 | 0.79 | ALDH1A1 (0.58) | ALDH1A1ITGB1MAPTHPGDL3MBTL1 | |
| SCHEMBL21358861 | 0.79 | ALDH1A1 (0.58) | ALDH1A1ITGB1MAPTHPGDL3MBTL1 | |
| SCHEMBL21358699 | 0.79 | ITGA4 (0.55) | ITGA4ALDH1A1ITGB1ITGA2 | |
| SCHEMBL21358701 | 0.79 | ITGA4 (0.55) | ITGA4ALDH1A1ITGB1ITGA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-16 | — | — | US | disclosed |
| EP-3765005-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | The Regents of the University of California (US) | 2021-01-20 | — | — | EP | disclosed |
| WO-2019178248-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | ITGB1, ITGB2, ITGA2 | ITGA4 15/4885TXNRD1 4418/4885ALDH1A1 382/4885 |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | ITGB1, ITGB2, ITGA2 | ITGA4 15/4885TXNRD1 4418/4885ALDH1A1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.